| HOME >> MEDICINE >> TECHNOLOGY |
Table 13: Gilead launch portfolio overview ($m), 2008-14 50
Table 14: Gilead core portfolio overview ($m), 2008-14 51
Table 15: Gilead expiry portfolio overview ($m), 2008-14 52
Table 16: Gilead prescription pharmaceutical sales by molecule type ($m), 2008-14 55
Table 17: Gilead prescription pharmaceutical sales by source ($m), 2008-14 57
Table 18: Total Gilead sales by business unit ($m), 2002-08 60
Table 19: Gilead operating revenue/cost analysis ($m), 2002-08 62
Table 20: Gilead operating cost ratio analysis (% of total revenues), 2002-08 63
Table 21: Gilead operating cost ratio analysis (% of total revenues), 2008-14 64
Table 22: Gilead operating revenue/cost analysis ($m), 2008-14 65
Table 23: Key products overview 68
Table 24: Atripla: overview 69
Table 25: Atripla: sales forecast ($m), 2008-14 70
Table 26: Truvada: overview 72
Table 27: Truvada: sales forecast ($m), 2008-14 73
Table 28: Viread: overview 75
Table 29: Viread: sales forecast ($m), 2008-14 76
Table 30: Truvada + rilpivirine: overview 78
Table 31: Truvada + rilpivirine: sales forecast ($m), 2008-14 79
Table 32: Letairis: overview 80
Table 33: Letairis: sales forecast ($m), 2008-14 81
Table 34: Gilead Sciences R&D pipeline (Phase I-registration) 83
TABLE OF FIGURES
Figure 1: The PharmaVitae Explorer 3
Figure 2: Gilead prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 6
Figure 3: Gilead's financial performance ($m), 2002-14 7
Figure 4: Sales of the leading HIV therapy players, 2002-14 ($m) 12
Figure 5: Gilead prescription pharmaceutical sales by source, and therapy area ($m), 2002-14 14
Figure 6:
'/>"/>
| SOURCE Reportlinker Copyright©2009 PR Newswire. All rights reserved |